FONDATION-IPSEN
23.5.2017 07:32:05 CEST | Business Wire | Press release
The Fondation IPSEN (1) contributes to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians. The Fondation IPSEN Endocrine Regulations Prize (2) will be presented today at the ECE (European Congress of Endocrinology) in Lisbon. An international jury (3) chaired by Professor Iain Robinson (National Institute for Medical Research, London, UK ), awarded the prize to Bruce Mc Ewen for his pioneering work on glucocorticoids, stress and neuronal degeneration.
The Fondation IPSEN(1) contributes to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians from different backgrounds. Created in 2002, the Endocrine Regulations Prize(2) of the Fondation IPSEN awards renowned specialists who made breakthrough discoveries or significant progress in the field. Pr Bruce McEwen has been awarded by an international jury(3) for his pioneering work on glucocorticoids, stress and neuronal degeneration. The prize will be presented at the ECE (European Congress of Endocrinology), followed by a lecture given by Bruce McEwen.
During his talk, Bruce McEwen will discuss about the role of the steroid
hormones that are produced in the brain which mediate every aspect of
brain function. This has broadened the definition of
‘neuroendocrinology’ to include the reciprocal communication between the
brain and the body via hormonal and neural pathways.
The brain is
the central organ of stress and adaptation to stress because it
perceives and determines what is threatening, as well as the behavioural
and physiological responses to the stressor. The adult and developing
brain possess remarkable structural and functional plasticity in
response to stress, including neuronal replacement, dendritic
remodelling, and synapse turnover. Stress causes an imbalance of neural
circuitry subserving cognition, decision-making, anxiety and mood. This
imbalance, in turn, affects systemic physiology via neuroendocrine,
autonomic, immune and metabolic mediators. In the short term, as for
increased fearful vigilance and anxiety in a threatening environment,
these changes may be adaptive. But, if the danger passes and the
behavioural state persists along with the changes in neural circuitry,
such maladaptation may need intervention with a combination of
pharmacological and behavioural therapies, as is the case for chronic
anxiety and depression. Moreover, adverse early-life experience, produce
lasting effects on brain and body over the life-course via epigenetic
mechanisms. While prevention is most important, the plasticity of the
brain gives hope for therapies that take into consideration brain–body
interactions.
Biography
Bruce S. McEwen obtained his Ph.D. in Cell
Biology in 1964 from The Rockefeller University.
He is a member
of the US National Academy of Sciences, the National Academy of
Medicine, and the American Academy of Arts and Sciences. He served as
President of the Society for Neuroscience in 1997-98. As a
neuroscientist and neuroendocrinologist, McEwen studies
environmentally-regulated, variable gene expression in brain, mediated
by circulating steroid hormones and endogenous neurotransmitters in
relation to brain sexual differentiation and the actions of sex and
stress hormones on the adult brain. His laboratory discovered adrenal
steroid receptors in the hippocampus in 1968 that was the gateway for
discovering effects of circulating hormones on cognitive function, mood
regulation and other CNS functions. His laboratory combines molecular,
anatomical, pharmacological, physiological and behavioral methodologies
and relates their findings to human clinical information. His current
research focuses on stress effects on amygdala and prefrontal cortex, as
well as hippocampus, and his laboratory also investigates sex hormone
effects and sex differences in these brain regions involved in cognitive
function and mood regulation. He served on the MacArthur Foundation
Research Network on Socioeconomic Status and Health, in which he has
helped to reformulate concepts and measurements related to stress and
stress hormones in the context of human societies. This led to the
concept of “allostatic load and overload” that describes the wear and
tear on the body and brain from chronic stress and related life style
behaviors that lead to dysregulation of physiological stress pathways
that are normally protective.
He is also a member of the National
Council on the Developing Child which focuses on biological embedding of
early life experiences and promoting healthy brain development.
He
is the co-author of a book with science writer, Elizabeth Lasley, for a
lay audience called “The End of Stress as We Know It”, published in
2002, and “The Hostage Brain” with science writer, the late Harold M.
Schmeck, Jr., published in 1994.
(1) The Fondation IPSEN
Established in 1983 under the
aegis of the Fondation de France, the ambition of the Fondation IPSEN is
to initiate a reflection about the major scientific issues of the
forthcoming years. The long-standing mission of the Fondation IPSEN is
to contribute to the development and dissemination of scientific
knowledge by fostering interaction between scientists and clinicians. It
has developed an important international network of scientific experts
who meet regularly at meetings known as Colloques Médecine et
Recherche
, dedicated to three main topics: neurosciences,
endocrinology and cancer science. Moreover the Fondation IPSEN has
started several series of meetings in partnership with the Salk
Institute, the Karolinska Institute as well as with the journals Cell
and Science
. The Fondation IPSEN produced several hundred
publications and more than 250 scientists have been awarded prizes and
grants.
www.fondation-ipsen.org
(2) The Endocrine Regulations Prize laureates
Created
in 2002, this Prize of
the Fondation Ipsen
has been
awarded to following the renowned specialists: Wylie VALE
(2002), Robert
LEFKOWITZ
(2003), Pierre CHAMBON
(2004), Thomas HÖKFELT
(2005), Roger CONE
(2006), William CROWLEY
(2007), Ronald
EVANS
(2008), Gilbert VASSART
(2009), Shlomo MELMED
(2010), Paolo SASSONE-CORSI
(2011), Jeffrey M. FRIEDMAN
(2012), Bert O’MALLEY
(2013), Maria I. NEW
(2014), C.
Ronald Kahn
(2015) and John W. FUNDER
(2016).
(3) Members of the jury
Iain ROBINSON
(National
Institute for Medical Research, London, UK)
, President
Xavier
BERTAGNA
(Hôpital Cochin, Paris, France)
Felipe
CASANUEVA
(University of Santiago de Compostela, Santiago de
Compostela, Spain)
Michael CONN
(Texas Tech
University Health Sciences Center, El Paso, USA)
Ezio GHIGO
(Ospedale Molinette, Turin, Italy)
Ilpo HUHTANIEMI
(Imperial
College Faculty of Medicine, London, UK)
Gérard KARSENTY
(Columbia
University Medical Center, New York, USA)
Paul KELLY
(Faculté
de Médecine Necker Enfants Malades, Paris, France)
Stafford
LIGHTMAN
(University of Bristol, Bristol, UK)
Günter
STALLA
(Max Planck Institute of Psychiatry, München, Germany
Phyllis
WISE
(University of Illinois, Urbana, USA).
View source version on businesswire.com: http://www.businesswire.com/news/home/20170522005878/en/
Contact:
Fondation IPSEN
Yannick TANGUY, Tel. : +33 (0)1 58 33 50 00
E-mail
: fondation@ipsen.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Grindr for Equality Commits to Connecting 10M to HIV Prevention by 202827.7.2026 16:31:00 CEST | Press release
New report finds PrEP awareness is high but access is low, as global HIV funding shrinks Grindr steps up Today at the 2026 International AIDS Conference, Grindr for Equality committed to connecting ten million LGBTQ+ people to HIV prevention by 2028, leveraging its platform reach to advance the global effort to end HIV by 2030. The commitment is rooted in Closing the Gap, a new Grindr for Equality report drawing on survey data from Grindr users across ten countries. The central finding is consistent across countries: people know about PrEP but they are not taking it. The barrier is access and the funding that existed to address it is disappearing. "Connecting people is what Grindr does at a scale and in communities that traditional public health systems don't effectively reach," said George Arison, CEO and Chairman of Grindr (NYSE: GRND). "The global HIV response is losing critical funding at the exact moment we should be accelerating to end HIV by 2030. Grindr has the reach and the re
InterSystems Launches Data Studio AI Assistant to Accelerate Enterprise Data Exploration and Insights27.7.2026 16:00:00 CEST | Press release
New Generative AI extension simplifies how teams explore, analyze, and visualize enterprise data InterSystems, a creative data technology provider powering some of the world's most important applications, today announced the general availability of InterSystems Data Studio™ AI Assistant, a new generative AI-powered extension for InterSystems Data Studio that helps organizations more easily understand, navigate, query, and visualize data through natural language interactions. As organizations move from AI experimentation to production deployments, many are discovering that the greatest challenge is not the AI model itself, but providing AI systems with access to trusted, current, and business-ready information. Enterprise data is often fragmented across applications, databases, cloud services, files, data warehouses, and departmental silos, making it difficult for users and AI systems to generate reliable insights. “Organizations are increasingly looking for ways to turn their data into
PMI U.S. Opens $1.2 Billion Aurora Campus, Strengthening U.S. Manufacturing and Export Capabilities27.7.2026 14:00:00 CEST | Press release
Landmark investment advances U.S. manufacturing leadership, creates high-quality jobs, and positions the Colorado location as a strategic production and export hub Philip Morris International Inc.’s (PMI) (NYSE: PM) U.S. businesses (PMI U.S.) today celebrated the opening of its Aurora, Colorado manufacturing campus, a landmark investment representing total capital expenditures of $1.2 billion from 2024-2028. The campus expands the company’s domestic manufacturing capabilities, strengthens supply chain resilience, and positions Aurora as a strategic production and export hub supporting future growth. The site began commercial production in July 2026 and produces ZYN nicotine pouches, joining PMI U.S.’s growing modern nicotine manufacturing network, which includes operations in Owensboro, Kentucky, and Wilson, North Carolina. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260727514086/en/ PMI U.S. Opens $1.2 Billion Aurora Cam
Tecnotree Strengthens LATAM Growth with New Digital Transformation Contracts Worth USD 8.8 Million27.7.2026 13:20:00 CEST | Press release
Tecnotree, a global leader in AI-native Digital Business Support Systems (BSS) and digital platform solutions, today announced it has secured new digital transformation contracts across Latin America with a combined value of USD 8.8 million, reinforcing the company’s continued commercial momentum and expanding its presence across one of its key strategic growth markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260727931342/en/ Tecnotree Strengthens LATAM Growth with New Digital Transformation Contracts Worth USD 8.8 Million Across the engagements, Tecnotree will deploy its AI-native digital platform and B2B Marketplace for enterprises to simplify customer and business operations through intelligent digital engagement, real-time monetization, digital commerce and partner ecosystem management and AI driven marketing and experience management. By providing a unified digital foundation, the platform enables communications
Pure Lithium Corporation Appoints Mercedes-Benz Battery Veteran Dr. Tobias Glossmann as Chief Product Officer27.7.2026 13:00:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated next-generation lithium metal battery company and developer of the patented Brine to Battery™ technology, today announced the appointment of Dr. Tobias Glossmann as Chief Product Officer. In this role, Dr. Glossmann will lead product and technology strategy, guiding the translation of Pure Lithium’s battery science into engineered products and directing the company’s product engineering efforts. Dr. Glossmann joins Pure Lithium after a 25-year career across Mercedes-Benz companies, most recently serving as Principal Systems Engineer at Mercedes-Benz Research & Development North America. His work spanned advanced battery technology development, from materials through complete battery systems, and he held companywide responsibility for high voltage safety. His career began in 2001 with battery systems development at DaimlerChrysler in Ulm, Germany, and later in Michigan, giving him more than two decades of experience across cell chemistry
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
